ClinicalTrials.gg
Not yet recruitingNCT07948954Updated Nov 19, 2026

Urolithin A During Bedrest in Older Adults

An interventional study of Urolithin A and Placebo in Muscle Loss in Elderly, Geriatric Health and Elderly (People Aged 65 or More), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Not yet recruiting. Open to participants aged 65 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Prevention

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Study summary

This study will determine whether oral urolithin A (UA) attenuates the loss of knee-extensor strength caused by 10 days of horizontal bed rest in older adults.

Read the detailed description

The randomized comparison will also assess muscle mass, cardiorespiratory fitness, physical performance and glucose tolerance, together with cellular mechanisms of muscle adaptation. Orthostatic tolerance, balance responses to galvanic vestibular stimulation (GVS), salivary cortisol, and oral and fecal microbiome profiles will provide complementary exploratory measures of adaptation and recovery.v

02

Conditions studied

  • Muscle Loss in Elderly
  • Geriatric Health
  • Elderly (People Aged 65 or More)

Keywords

  • Geriatric
  • muscle
  • health
  • bedrest
  • elderly
  • natural supplement
03

In context

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women at least 65 years of age at enrolment, with a recruitment target of equal numbers of each sex
  • English or French speaking
  • Females not of
  • Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication/supplements habits for the duration of the study
  • Physically inactive, defined for eligibility as reporting no more than 2.5 hours of moderate-to-vigorous physical activity per week.

Exclusion criteria

Exclusion Criteria:

  • Participated in a clinical trial within 90 days of screening or more than 4 times in the previous year.
  • Neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation.
  • Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.
  • Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.
  • History of cancer in the last 6 months.
  • On any medications including NHPs/living with medical conditions that would compromise the study outcome or the safety of the research participant. For any supplements deemed acceptable, participants must be on a stable dose of allowed supplements/medications for at least 3 months prior to enrollment. All concomitant therapies will be documented.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Bed rest-Urolithin A group (BR-UA)

    Participants in BR-UA group will receive a total of 1,000 mg of UA orally each day.

    Dietary Supplement: Urolithin A

  • Placebo comparator
    BR-PLA group (C)

    Participants in group "C" will receive matching placebo.

    Dietary Supplement: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in knee extensor strength using biodex at baseline and following the intervention.

    To determine whether UA supplementation reduces the percentage loss of maximal voluntary isometric knee-extensor strength (N) using Biodex between baseline and recovery, compared with placebo.

    Time frame: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)

  2. Changes in V02 using indirect calorimetry at baseline and following the intervention.

    To compare the effects of UA and placebo on cardiorespiratory fitness function using peak oxygen uptake (VO2peak) between baseline and recovery, compared with placebo.

    Time frame: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)

Secondary outcomes

  1. Changes in body composition using DEXA scan at baseline and following the intervention.

    To determine whether UA supplementation had an effect on changes in fat free mass and fat mass using the DEXA scan between baseline and recovery, compared with placebo.

    Time frame: Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)

  2. Changes in mitochondrial respiration at baseline and following the intervention.

    To determine whether UA supplementation had an effect on changes in mitochondrial respiration and function using the OROBORUS from muscle biopsy samples between baseline and recovery, compared with placebo.

    Time frame: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)

  3. Changes in muscle mass at baseline and following the intervention.

    To determine whether UA supplementation had an effect on changes in muscle mass using CT scan between baseline and recovery, compared with placebo.

    Time frame: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022 Dec 13;328(22):2252-2264. doi: 10.1001/jama.2022.21022. PubMed 36511921 ↗
  • Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hrobjartsson A. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025 Apr 28;389:e081477. doi: 10.1136/bmj-2024-081477. PubMed 40294953 ↗
  • Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123. PubMed 40228833 ↗
  • Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. TCPS 2. 2022. https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2022.html.
  • Health Canada. Notice: Period reduced for keeping clinical trial records for drugs and natural health products. 28 March 2022. https://www.canada.ca/en/health-canada/services/clinical-trials/notice-period-reduced-keeping-records-drugs-natural-health-products.html. Accessed 25 September 2026.
  • Mirzayi C, Renson A; Genomic Standards Consortium; Massive Analysis and Quality Control Society; Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, Braun J, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, Ruhlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L. Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med. 2021 Nov;27(11):1885-1892. doi: 10.1038/s41591-021-01552-x. Epub 2021 Nov 17. PubMed 34789871 ↗
  • Stalder T, Kirschbaum C, Kudielka BM, Adam EK, Pruessner JC, Wust S, Dockray S, Smyth N, Evans P, Hellhammer DH, Miller R, Wetherell MA, Lupien SJ, Clow A. Assessment of the cortisol awakening response: Expert consensus guidelines. Psychoneuroendocrinology. 2016 Jan;63:414-32. doi: 10.1016/j.psyneuen.2015.10.010. Epub 2015 Oct 20. PubMed 26563991 ↗
  • Utz KS, Korluss K, Schmidt L, Rosenthal A, Oppenlander K, Keller I, Kerkhoff G. Minor adverse effects of galvanic vestibular stimulation in persons with stroke and healthy individuals. Brain Inj. 2011;25(11):1058-69. doi: 10.3109/02699052.2011.607789. Epub 2011 Aug 31. PubMed 21879800 ↗
  • Gouspillou G, Sgarioto N, Kapchinsky S, Purves-Smith F, Norris B, Pion CH, Barbat-Artigas S, Lemieux F, Taivassalo T, Morais JA, Aubertin-Leheudre M, Hepple RT. Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans. FASEB J. 2014 Apr;28(4):1621-33. doi: 10.1096/fj.13-242750. Epub 2013 Dec 26. PubMed 24371120 ↗
  • Holwerda AM, Paulussen KJM, Overkamp M, Smeets JSJ, Gijsen AP, Goessens JPB, Verdijk LB, van Loon LJC. Daily resistance-type exercise stimulates muscle protein synthesis in vivo in young men. J Appl Physiol (1985). 2018 Jan 1;124(1):66-75. doi: 10.1152/japplphysiol.00610.2017. Epub 2017 Sep 21. PubMed 28935828 ↗
  • Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70. doi: 10.2337/diacare.22.9.1462. PubMed 10480510 ↗
  • Cefis M, Marcangeli V, Hammad R, Granet J, Leduc-Gaudet JP, Gaudreau P, Trumpff C, Huang Q, Picard M, Aubertin-Leheudre M, Belanger M, Robitaille R, Morais JA, Gouspillou G. Impact of physical activity on physical function, mitochondrial energetics, ROS production, and Ca2+ handling across the adult lifespan in men. Cell Rep Med. 2025 Feb 18;6(2):101968. doi: 10.1016/j.xcrm.2025.101968. Epub 2025 Feb 10. PubMed 39933528 ↗
  • Hajj-Boutros G, Sonjak V, Faust A, Balram S, Lagace JC, St-Martin P, Divsalar DN, Sadeghian F, Liu-Ambrose T, Blaber AP, Dionne IJ, Duchesne S, Kontulainen S, Theou O, Morais JA. Myths and Methodologies: Understanding the health impact of head down bedrest for the benefit of older adults and astronauts. Study protocol of the Canadian Bedrest Study. Exp Physiol. 2024 May;109(5):812-827. doi: 10.1113/EP091473. Epub 2024 Feb 19. PubMed 38372420 ↗
  • Cipriani E, et al. Mesurer le genre en recherche sur les humains, un nouveau questionnaire adapté. Unité de Soutien SSA Québec. 2022:1-16.
  • Marusic U, Narici M, Simunic B, Pisot R, Ritzmann R. Nonuniform loss of muscle strength and atrophy during bed rest: a systematic review. J Appl Physiol (1985). 2021 Jul 1;131(1):194-206. doi: 10.1152/japplphysiol.00363.2020. Epub 2021 Mar 11. PubMed 33703945 ↗
  • Singh A, D'Amico D, Andreux PA, Fouassier AM, Blanco-Bose W, Evans M, Aebischer P, Auwerx J, Rinsch C. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022 May 17;3(5):100633. doi: 10.1016/j.xcrm.2022.100633. PubMed 35584623 ↗
  • Liu S, D'Amico D, Shankland E, Bhayana S, Garcia JM, Aebischer P, Rinsch C, Singh A, Marcinek DJ. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144279. doi: 10.1001/jamanetworkopen.2021.44279. PubMed 35050355 ↗
  • Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14. PubMed 32694802 ↗
  • Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Felix AA, Williams EG, Jha P, Lo Sasso G, Huzard D, Aebischer P, Sandi C, Rinsch C, Auwerx J. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016 Aug;22(8):879-88. doi: 10.1038/nm.4132. Epub 2016 Jul 11. PubMed 27400265 ↗
  • Hvid LG, Suetta C, Nielsen JH, Jensen MM, Frandsen U, Ortenblad N, Kjaer M, Aagaard P. Aging impairs the recovery in mechanical muscle function following 4 days of disuse. Exp Gerontol. 2014 Apr;52:1-8. doi: 10.1016/j.exger.2014.01.012. Epub 2014 Jan 18. PubMed 24447828 ↗
  • Hajj-Boutros G, Sonjak V, Faust A, Hedge E, Mastrandrea C, Lagace JC, St-Martin P, Naz Divsalar D, Sadeghian F, Chevalier S, Liu-Ambrose T, Blaber AP, Dionne IJ, Duchesne S, Hughson R, Kontulainen S, Theou O, Morais JA. Impact of 14 Days of Bed Rest in Older Adults and an Exercise Countermeasure on Body Composition, Muscle Strength, and Cardiovascular Function: Canadian Space Agency Standard Measures. Gerontology. 2023;69(11):1284-1294. doi: 10.1159/000534063. Epub 2023 Sep 15. PubMed 37717560 ↗
  • Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007 Apr 25;297(16):1772-4. doi: 10.1001/jama.297.16.1772-b. No abstract available. PubMed 17456818 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2027; primary completion for Aug 2031, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 19, 2026
StartEst.
Aug 1, 2027
Primary completionEst.
Aug 2031
CompletionEst.
Aug 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948954
Responsible party
Jose Morais (Professor, Faculty of Medicine, Principal Investigator, Senior Physician, MUHC Senior Scientist, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Nov 19, 2026
Start date
Aug 1, 2027 (estimated)
Primary completion
Aug 2031 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Sharmila Research Coordinator Baccalaureate Nurse
Contact
reachlab@muhc.mcgill.ca
1+514-984-9975
Guy Hajj Boutros
Contact
reachlab@muhc.mcgill.ca
514-501-9975
Jose A Morais, Medical Doctor
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urolithin A Supplement

Start the discussion